← Back to Search

Antimicrobial Wound Dressing

Intervention Period for Foot Ulcer

N/A

Waitlist Available

Research Sponsored by Chester Ho, MD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion over four months

Awards & highlights

Study Summary

This trial evaluates the effectiveness of a new wound dressing, NanoSALV, to improve chronic wound care, cost-savings, patient satisfaction, and healing time. Interviews and observations are used to assess usability.

Eligible Conditions

Diabetic Foot Ulcers
Pressure Ulcer
Leg Ulcer
Venous Leg Ulcer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion over four months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion over four months

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion over four months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Process Improvement

Quality Improvement

Soft Cost Savings

+2 more

Secondary outcome measures

Adverse events

Patient preference

Patient satisfaction - comfort

+4 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention PeriodExperimental Treatment1 Intervention

Patients receive the intervention, NanoSALV wound dressing, in the consecutive four weeks following the control period

Group II: Control PeriodActive Control1 Intervention

Patients receive the current standard of care for their chronic wound in the first four weeks of enrollment Standard of care (SOC) involves: Offloading of pressure as needed High compression bandaging, as needed Debridement, as needed Nutrition management, as needed SOC dressings, such as silver/iodine dressings, antibiotic ointment Management of infection Management of pain during debridement, as needed

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

NanoSALV Catalytic

2022

N/A

~50

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Chester Ho, MDLead Sponsor

Alberta Health servicesOTHER

158 Previous Clinical Trials

649,622 Total Patients Enrolled

NanoTess Inc.UNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the purpose of this clinical investigation?

"The primary metric for this four-month study is User Satisfaction. Secondary objectives include assessing Patient satisfaction - ease of use and overall satisfaction with NanoSALV, as well as Wound percent volume change measured by photography and 3D camera tracing."

Answered by AI

Are there any opportunities to participate in this investigation currently available?

"As listed on clinicaltrials.gov, this particular trial is not currently seeking participants; it was first posted on December 5th 2022 and last updated November 8th 2022. However, 1134 other studies are actively recruiting patients at the present time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pivotal Study of an Antimicrobial Wound Dressing to Treat Chronic Wounds

Chester Ho, MD 2022. "Pivotal Study of an Antimicrobial Wound Dressing to Treat Chronic Wounds". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05619237.